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1. Introduction
  With the development of social economy and extension of 
human lifespan, osteoporosis (OP) has become an important 
health problem in the elderly population. OP results from 
loss of the dynamic balance of bone formation and bone 
resorption that normally maintains bone mass stable 
relatively[1]. Treatment for OP is primarily divided into 
two categories, anti-resorptive and anabolic (osteogenic) 
agents[2,3]. Elcatonin is a commonly-used drug for senile 
OP, primarily by inhibiting bone resorption and improving 
bone mineral density (BMD), but it is unable to maintain 
normal bone mass and bone strength[4]. Anabolic agents 
can make up for these deficiencies. Anabolic therapy can 
increase BDM and quality, while reducing the risk for 
osteoporotic fractures through stimulation of new bone 
growth. Teriparatide [rhPTH (1-34)], a recombinant human 
parathyroid hormone (rhPTH) analogue, maintains the major 
function of PTH hormone (84 amino acids) and has been an 
option for treating OP in a decade. Although the net effect of 
Objective: To evaluate the efficacy and safety of rhPTH (1-34) vs. elcatonin. Methods: Sixty 
patients with primary OP were randomly divided into two groups according to the ratio of 3:1. 
rhPTH (1-34) group (PTH group) was treated with subcutaneous injection of rhPTH (1-34) 20 毺g 
daily for 18 months, and the elcatonin group (CT group) was treated with intramuscular injection 
of elcatonin 20 U weekly for 12 months. Bone mineral density (BMD) of the lumbar spine 2-4 (L2-4) 
and femoral neck, serum calcium and phosphorus, urinary calcium, serum bone specific alkaline 
phosphatase (BSAP), and urinary c-terminal telopeptides of type 栺 collagen/creatinine (uCTX-
栺/Cr) were tested at baseline, and 6, 12, and 18 months after treatment. Results: In PTH group, 
BMD of L2-4 at 6, 12, and 18 months, BDM of femoral neck at 18 month, BSAP at 6 and 12 months 
and uCTX-栺/Cr at 6, 12 and 18 months were all significantly raised. In CT group, BMD of L2-4 at 
12 month and that of femoral neck at 12 and 18 months were significantly elevated, while BSAP 
was significantly decreased at 12 and 18 months, and no significant difference on CTX-栺/Cr was 
observed. When BMD growth and growth rate between two groups were compared, PTH group 
had better improvement in L2-4 BMD and growth rate than CT group at 6, 12, and 18 months. BMD 
growth and growth rate of femoral neck at 12 month and its growth at 18 month in CT group were 
higher than in PTH group, but there was no significant difference between two groups regarding 
the growth rates at 18 month. Besides, there were no significant differences regarding the rates 
of adverse reactions between two groups. Conclusions: rhPTH (1-34), is safe and effective in 
the treatment of primary OP. It is superior to elcatonin in improving vertebral BMD at onset time, 
growth rate and growth range, but inferior to elcatonin at BMD of femoral neck.
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PTH in some circumstances like primary hyperparathiridism 
could be catabolic[4], small doses of intermittent application 
of parathyroid hormone (PTH) has a direct effect of inducing 
bone formation through stimulation of osteoblast activity 
and inhibition of apoptosis[5,6]. It can increase the bone 
mass of patients and reduce the risk of fracture. Several 
studies in Europe and United States have confirmed that 
rhPTH (1-34) has remarkable benefits for elderly patients 
with OP[7,8]. There are few clinical studies about this drug in 
Asian population[9]. Hence, this study aimed to make further 
evaluation on the efficacy and safety of rhPTH (1-34) in 
improving BMD of primary OP and made a comparison with 
elcatonin, a traditional antiresorptive agent. 
2. Materials and methods
2.1. Patients
  Sixty patients with primary OP were recruited in Sichuan 
Provincial People’s Hospital from March, 2008 to January, 
2009. Inclusion criteria were as follows: (1) OP was diagnosed 
according to WHO diagnostic criteria[10], with one of the 
following: a) BMD T-score of lumbar spine 2-4 (L2-4) or of 
femoral neck is less than - 2.5 SD; b) One place of L2-4 was 
compressed deformation, and T-score less than -1.0S D; (2) 
The females at the age of 50-79 had more than 3 years of 
menopause, and males were at the age of 60-79. Exclusion 
criteria included: (1) any non-primary OP bone disease 
and other metabolic bone diseases; (2) liver and kidney 
dysfunction; (3) patients with severe cardiac, hematological, 
psycho, and nervous system diseases; (4) cancer and other 
serious progressive disease; (5) patients treated with anti-
OP drugs of bisphosphonate in recent 6 months; (6) patients 
took drugs that affected bone metabolism in recent 1 month. 
All patients signed the informed consent form voluntarily. 
Among 60 patients, and 53 cases could be evaluated and 7 
quitted because of adverse reactions during treatment. All 
participants signed informed consent before enrollment into 
the study according to Declaration of Helsinki, and the study 
was approved by the ethics committee.  
2.2. Methods
  According to visiting order, the patients were randomly 
assigned to two groups: PTH group and CT group 
according to the ratio of 3:1. PTH group (45 cases) received 
subcutaneous injection of rhPTH (1-34) (Shanghai United 
Cell Biotechnology Co., Ltd production), 20 毺g once daily, 
and continuously for 18 months. CT group (15 cases) received 
intramuscular injection of elcatonin (Asahi Kasei Corporation 
production), 20 U once a week, 12 months of continuous 
treatment. During treatment, both groups received Caltrate 
D 600 mg, once daily, which contained 1 500 mg of calcium 
carbonate (providing 600 mg of calcium) and 125 IU of 
vitamin D3 (Wyeth Pharmaceutical Co., Ltd) for 18 months 
continuously. Drugs that could affect bone metabolism were 
banned, such as bisphosphonates, glucocorticoids, sex 
hormones, bone-strengthening tablet. 
2.3. BMD, bone turnover and biochemical markers 
measurements
  BMD in L2-4 and femoral neck were measured by dual 
energy X-ray absorptiometry using densitometers from GE 
Lunar Corp (DPX-MD, USA). Serum calcium and phosphorus 
were determined by ALYMPUSAU5400/AU2700 automatic 
biochemical analyzer. Urinary calcium was tested by 
VITROS250 automatic dry-type chemistry analyzer. Bone 
specific alkaline phosphatase (BSAP, Immunodiagostic 
System Ltd, USA) and urinary c-terminal telopeptides of 
type 栺 collagen/creatinine (uCTX-栺/Cr, Nordic Bioscience 
Diagnostics a/s, Denmark) were use as bone formation and 
bone resorption marker, respectively. BSAP and uCTX-栺
were measured by enzyme-linked immunosorbent assay 
(SEAC Company, Italy), the coefficient of variation within 
batch <5%, between batch <8%. Urine CTX-栺was corrected 
by urine creatinine, with correction formula: uCTX-栺/Cr
(毺g/mmolCr)=measured urine CTX-栺 (毺g/L)/urine 
creatinine (mmol/L). During observation, the patients were 
followed up once every 2 months, 9 times in total. BMD, 
biochemical and bone metabolism markers mentioned above 
were measured again when the followed-up was conducted 
at 6, 12 and 18 months. Additionally, adverse reactions were 
recorded. The above-mentioned indexes were all compared 
before and after treatment. 
2.4. Statistical analysis
  Descriptive statistics of the study subjects were summarized 
with means暲standard deviation (SD) for continuous 
variables, number and percentages for categorical items. 
The normality of the distribution of the study sample was 
assessed by Kolmogorov-Smirnov test. Student’s t test 
was used for the group differences of continuous items 
and Pearson’s 氈
2 test for categorical items at baseline. 
Independent-sample t test was used to compare BMD and 
serum biochemical markers from baseline to endpoint 
between two treatment groups. The paired t test was used to 
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assess the changes from baseline to endpoint within each 
treatment group. The adverse reactions experienced by 
subjects in the study were analyzed using Pearson’s 氈
2 test. 
All statistical tests were two sided, with an 毩 level of 0.05. 
Statistical analysis was performed by SPSS 17.0.
3. Results
3.1. Demographics of patients
  Following successful screening, a total of 60 patients 
with primary OP were enrolled in the current study and 
randomly assigned to two groups as the intent-to-treat (ITT) 
population. The demographics of patients were summarized 
in Table 1. There were no statistically significant differences 
between both groups. Additionally, 25 of the overall patients 
(41.7%) suffered from fracture prior to the treatment. During 
the study period, 5 patients in PTH group (11.1%) and 2 in CT 
group (13.3%) discontinued intervention due to withdrawal of 
consent. Finally, a total of 53 patients completed the entire 
study protocol (Figure 1).
Figure 1. Changes of L2-4 and femoral neck (FN) BMD before and 
after treatment at 6, 12 and 18 months. 
3.2. Changes in BMD at the L2-4 and FN
  Compared with treatment before, L2-4 BMD in PTH group 
had a significant increase at 6, 12 and 18 months. In CT 
group, L2-4 BMD was increased significantly at 12 month, 
and showed higher values than treatment before, but the 
difference was not significant (Figure 2A). The femoral neck 
BMD was significantly increased in PTH group at 18 month, 
while in CT group at 12 and 18 months (Figure 2B). 
3.3. Changes of biochemical markers before and after 
treatment
  In PTH group, the serum calcium levels were increased 
significantly at 6 and 12 months, but returned to normal 
at 18 month compared with treatment before. In CT group, 
the serum calcium showed no significant difference (Figure 
3A). In PTH group, the serum phosphorus levels were 
increased significantly at 6, 12 and 18 months. No significant 
differences were observed in CT group (Figure 3B). Regarding 
the urinary calcium level, no significant differences were 
observed before and after treatment (Figure 3C). 
Figure 2. Changes of biochemical markers before and after treatment 
at 6, 12 and 18 months.
Figure 3. Changes of bone markers before and after treatment at 6, 12 
and 18 months.
3.4. Changes of bone metabolism markers before and after 
treatment 
  Compared with treatment before, BSAP levels were 
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increased significantly in PTH group at 6 and 12 months, 
while decreased significantly in CT group at 12 and 18 
months. There were significant differences between two 
groups regarding BSAP levels respectively at 6, 12 and 
18 months (Figure 4A). Compared with treatment before, 
uCTX-栺/Cr levels were increased significantly in PTH 
group at 6, 12 and 18 months, but no significant differences 
were observed in CT group. Significant differences were 
showed between two groups regarding uCTX-栺/Cr levels 
respectively at 6, 12 and 18 months (Figure 4B). 
Figure 4. Changes of bone metabolism markers before and after 
treatment at 6, 12 and 18 months. 
3.5. Comparison on BMD growth and its growth rate between 
two groups
  Compared with CT group, PTH group had a higher growth 
in L2-4 BMD, even a rapid growth rate at 6, 12 and 18 months. 
Regarding the femoral neck BMD, no significant differences 
on growth and growth rate were observed at 6 month between 
these two groups. BMD growth and growth rate of femoral 
neck at 12 month and its growth at 18 month in CT group 
were higher than in PTH group, but there was no significant 
difference between two groups regarding the growth rates at 
18 month.
3.6. Adverse reaction
  The incidence of drug-related adverse reactions was 35.6% 
(16/45) in PTH group, in which 5 cases quitted, while 33.3% 
(5/15) in CT group, in which 1 case quitted. There was no 
significant difference between two groups with regard to the 
incidence of adverse reactions (P>0.05). No severe drug-
related adverse reactions occurred in both groups. The 
main adverse reactions in PTH group were dizziness (11.1%), 
fatigue (2.2%), pruritus at the injection site (8.9%), rash (8.9%) 
and transient hypercalcemia (28.9%), while those in CT group 
included dizziness (13.3%), fatigue (13.3%) and elevated 
transaminases (6.7%). The patients were not given any 
special treatment for adverse reactions. Two cases suffered 
from new fractures throughout the follow-up process in PTH 
group, respectively T-12 vertebra compression fracture and 
occipital linear fracture, while 1 from new fracture of right 
fibular head linear fracture in CT group. Compared with the 
Table 1 
Baseline characteristics of patients enrolled in the current study.
Characteristica PTH group (n=45) CT group (n=15) P value
Gender (male/female) 4/41 1/14 1.000
Age (years) 65.1 暲 7.6 65.5 暲 8.7 0.865
Course of disease (years)   7.0 暲 4.4   7.2 暲 5.1 0.884
Fracture prior to the treatment (n, %) - - 0.782
None 25 (55.6) 10 (66.7) -
One body site 17 (37.8) 4 (26.7) -
Two body sites 2 (4.4) 1 (6.7) -
Three or more body sites 1 (2.2) 0 (0) -
L2-4 BMD (g/cm
2) 0.764 暲 0.088 0.787 暲 0.090 0.387
Femoral neck BMD (g/cm2) 0.719 暲 0.145 0.673 暲 0.143 0.290
Serum Ca (mmol/L) 2.52 暲 0.15 2.55 暲 0.19 0.533
Serum P (mmol/L) 1.08 暲 0.17 1.16 暲 0.18 0.125
Urinary Ca (mmol/L) 3.39 暲 1.56 3.28 暲 1.44 0.811
BSAP (毺g/L) 27.16 暲 10.88 25.04 暲 10.69 0.514
uCTX-栺/Cr (毺g/mmol.Cr) 253.71 暲 145.83 204.69 暲 163.09 0.364
Note: a Data were presented as means暲SD unless stated otherwise. PTH, recombinant human parathyroid hormone (1-34); CT, elcatonin; L2-4, 
the lumbar spine 2-4;  uCTX-栺/Cr, urinary c-terminal telopeptides of type 栺 collagen/creatinine.
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incidence of new fracture between two groups, there was no 
significant difference (P>0.05).
4. Discussion
  PTH secreted by the parathyroid participates in the 
regulation of calcium and phosphorus metabolism. It 
increases bone formation by several mechanisms: (1) 
regulate bone growth by mediating the proliferation and 
differentiation of osteoblasts[11]; (2) activate the signaling 
pathway of anti-apoptosis rapidly so as to inhibit apoptosis 
of osteoblasts[12]; (3) stimulate osteoblasts to produce local 
regulatory factors, such as insulin-like growth factor 
1 (IGF-1) and transforming growth factor that promote 
osteogenesis[13]; (4) intermittent PTH is associated with 
sustained stimulation of receptor activator of nuclear factor 
Kappa B ligand[14]. A current concept on its mechanism is 
related to what has been termed “anabolic window”, which 
is defined as a period when bone formation is greater than 
bone resorption. The basis for the anabolic window is due 
to its ability to stimulate bone formation and block bone 
resorption[15]. With increasing importance of biological 
balance of bone formation/resorption in bone homeostasis, 
rhPTH has become a research hotspot in the treatment of 
OP[16-18].
  In the current study, we compared the effects of rhPTH 
(1-34) with elcatonin. Continuous administration of 
elcatonin more than one year increased the incidence of 
pituitary tumors[19], so we limited the duration of elcatonin 
administration to 12 months in this trial. BSAP and CTX-
栺 were chosen as markers for evaluating bone turnover, 
because BSAP produced by osteoblasts reflected the 
activity of osteoblast and bone formation, and CTX-栺
, a degradation product of bone collagen, reflected bone 
resorption. Our data showed that both rhPTH (1-34) and 
elcatonin could significantly increase vertebral BMD and 
femoral neck BMD. The different action mechanism of both 
anti-OP agents can be appreciated by the levels of BSAP 
and uCTX-栺/Cr: (1) BSAP was significantly elevated in 
PTH group, suggesting that rhPTH (1-34) improves BMD 
by promoting bone formation. On the contrary, BSAP in 
CT group was significantly decreased; (2) uCTX-栺/Cr was 
increased during rhPTH (1-34) treatment, suggesting that it 
simultaneously increases bone resorption when stimulating 
bone formation, which further stimulates and promotes bone 
formation. This finding is consistent with those of previous 
studies. Intermittent low dose of PTH may maximize the 
effect of bone formation and minimize the effect of bone 
absorption[20-22]. The temporal changes in BSAP and uCTX-
栺/Cr levels showed that there was a “synthetic window” 
when the bone formation was significantly greater than bone 
resorption, leading to the largest osteogenic effect: in PTH 
group, BSAP reached its peak at 6 month, and uCTX-栺/
Cr reached the peak at 12 month. However, the vertebral 
and BMD femoral neck (especially L2-4 BMD ) progressively 
increased. rhPTH (1-34) showed better results compared with 
elcatonin in improving vertebral BMD. Regarding the femoral 
neck BMD, as compared with rhPTH (1-34), elcatonin was 
able to maintain its effect for additional 6 months after the 
12-month treatment. However, at 18 months, no significant 
difference was observed between both groups regarding the 
growth rate of femoral neck BMD. Hence, this study reveals 
that a small dose of rhPTH (1-34) has an anabolic effect, and 
this effect is better for cancellous bone, which is consistent 
with prior studies[4]. 
  In this study, hypercalcemia was observed in 28.9% of 
patients in PTH group, relatively higher than previously 
reported data[23]. Nevertheless, it neither required any 
medical treatment nor led to discontinuation. With exception 
of the study by Li et al[24], most studies were limited to 12 
months. In this study, the limitation included: (1) The sample 
size was small; (2) The courses of treatment in these two 
groups were not entirely consistent. Hence, the conclusion 
may not be necessarily suitable for majority of patients with 
OP, which may explain the difference on PTH on BMD effects 
of femoral neck. Currently, the longest treatment period of 
OP with rhPTH (1-34) is limited to 18 months in Europe[25]. 
However, a growing interest is how to maintain its effect on 
BMD growth and fracture prevention after treatment[26,27]. We 
speculate that a sequential combination can be considered 
(perhaps rhPTH (1-34) followed by elcatonin) due to their 
different action mechanisms and respective advantages. 
Hence, the results in this study provide a supporting 
evidence for rhPTH (1-34) safe administration for up to 18 
months to treat primary OP in Asian population. 
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